AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06171308 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chinese moxibustion apparatus
Description: The study group was treated with traditional Chinese moxibustion and western medicine. The control group was treated with blank moxibustion and western medicine.~1. The study group: Using the moxibustion, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~2. The control group: Using the moxibustion with blank patch, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~3. The treatment period is 4 weeks, which is a course of treatment, and the observation period is 8 weeks.
Study NCT05761184 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum collection for proteomic analysis
Description: Serum collection for proteomic analysis
Study NCT05661968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online educational program
Description: The intervention group will receive an online educational program, containing current information on low back pain management according to international clinical practice guidelines. Program content includes recommendations on assessment, diagnosis, and treatment of low back pain. The online program has 6 units of studies, with the content offered in the formats of video classes, infographics, texts, websites and clinical cases. The participant must complete the course within 6 weeks and will be able to set their own pace. Participants in the intervention group will receive their login and access password via email.
Study NCT05795335 — intervention group
Intervention type: DRUG
Intervention: CDK4/6 inhibitor
Description: CDK4/6 inhibitors
Study NCT05486286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NCKU-NG system
Description: A live-video system (NCKU-NG system) was developed to assist in the placement of enteral feeding tubes. This system consists of a camera and light source that can be inserted into the commercial NG tube to view live video during feeding tube placement. Manual air insufflation may aid feeding tube placement and improve visualization of anatomic landmarks. After the procedure, an abdominal X-ray is done to confirm the position of the feeding tube.
Study NCT06260865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MORA Cure
Description: MORA Cure (ETH-01K), developed by EverEx, Inc., is a digital therapeutics (S/W medical device) designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioural therapy for patients with patellofemoral pain syndrome.
Study NCT06260865 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: In the control group, education is delivered and self-exercise is recommended.
Study NCT05481320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH VN Phone Intervention
Description: 4-6 intervention sessions delivered via phone over the course of 1-3 months.
Study NCT05481320 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Control
Description: A single phone session providing education about dementia.
Study NCT05287763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatal soft tissue graft harvesting
Description: After local anaesthesia, a horizontal incision 2 mm apically from the gingival margin will be carried out using a #15C blade. The standardized rectangular graft with a thickness of 1.5 mm will be harvested from distal aspect of canine till first molar. The graft will be lifted and separated using tissue forceps and a blade till it is free from all sides.
Study NCT05287763 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palatal soft tissue graft harvesting
Description: After local anaesthesia, a horizontal incision 2 mm apically from the gingival margin will be carried out using a #15C blade. The standardized rectangular graft with a thickness of 1.5 mm will be harvested from distal aspect of canine till first molar. The graft will be lifted and separated using tissue forceps and a blade till it is free from all sides.
Study NCT05458583 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Baseline periodontal measurements (T0)
Description: Periodontal measurements including plaque index, gingival index and calculus index were recorded at the bonding session.
Study NCT05458583 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Periodontal measurements (T1)
Description: Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 6 months after bonding.
Study NCT05458583 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Periodontal measurements (T2)
Description: Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 12 months after bonding.
Study NCT05458583 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Retainer failure rates
Description: A retainer with at least one composite pad detachment was considered to be a failure during 1-year follow-up.
Study NCT04740632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Nutritional Counseling by a multidisciplinary team
Description: Active diet therapy, instructions on reading labels, cross-contamination, allergen-free, foods recipes
Study NCT05405881 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Proprioception measurement tool
Description: No intervention, as it is a psychometric properties study
Study NCT04252001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YESS! game
Description: The YESS! game is a real-life game for smartphone or tablet in which the player has to solve a mystery. The adolescent plays an active role in the course of the story. This results in an interactive experience. During the game, the adolescent is challenged with regard to self-management and responsible behaviour in general life, with parallels to medical selfmanagement and responsible behaviour.~The adolescent has to decide at several different moments whether to take action or not, whether to accept help or not and whether to share (fictive) confidential information or not. Other aspects that are covered are 'taking responsibility' and 'being on time'. The choices the adolescent makes throughout the game are registered in a coded manner, for later analysis. The game is available in Dutch, English and Spanish.
Study NCT04252001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Snake '97
Description: Snake '97 is a game for smartphone or tablet which is free and can be downloaded in the App Store. The game is a remake of the original snake on the mobile phone in 1997 in which the player moves the snake around and makes the snake 'consume food' (little dots) which causes the snake to grow longer. The goal is to make the snake as large as possible. The game has 12 difficulty levels.
Study NCT04252001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transition-toolkit
Description: The transition toolkit consists of paper cards with assignments, ideas and tips regarding medical self-management.
Study NCT06225453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized perioperative blood pressure management strategy
Description: In this group, perioperative mean arterial pressure and systolic blood pressure are maintained at no less than -20% of the baseline values of each patient.
Study NCT06225453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional perioperative blood pressure management strategy
Description: In this group, perioperative mean arterial pressure and systolic blood pressure are maintained at ≥65 mmHg and ≥90 mmHg, respectively, in all patients.
Study NCT04760626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 52 weeks.
Study NCT04760626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine 100U/mL
Description: Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
Study NCT04760626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
Study NCT04760626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine 300U/mL
Description: Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
Study NCT06476249 — intervention group
Intervention type: OTHER
Intervention: without
Description: without
Study NCT05943704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beef broth
Description: It indicates if the child has allergy of Beef or not.
Study NCT05494918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN003
Description: JSKN003 is to be administered via intravenous (IV) dose
Study NCT04093076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-4500
Description: INO-4500 will be administered ID on Day 0 and Week 4.
Study NCT04093076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 2000
Description: EP using the CELLECTRA™ 2000 device will be administered following ID drug administration.
Study NCT04093076 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CELLECTRA™ 2000
Description: EP using the CELLECTRA™ 2000 device will be administered following ID drug administration.
Study NCT04093076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered ID on Day 0 and Week 4.
Study NCT06111625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blinatumomab
Description: Blinatumomab was administered via a peripherally inserted central catheter (PICC) with an initial dosage of 8 μg/day. The dosage gradually escalated to 28 μg/day, with a total dose of 175 μg, infused over 5 to 10 days. To mitigate the risk of cytokine release syndrome (CRS), dexamethasone at a dose of 20 mg was administered 12 hours before the onset of blinatumomab infusion.
Study NCT05876832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XY0206
Description: Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,37.5mg at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until the subjects meet the withdrawal criteria.
Study NCT05876832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salvage Chemotherapy
Description: Low-dose Cytarabine (LoDAC) or azacitidine, fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) or mitoxantrone, etoposide, cytarabine (MEC)will be administered by subcutaneous (SC) and/or intravenous (IV) injections.
Study NCT06104072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REHACOM Software
Description: It is a computer-based cognitive rehabilitation test that includes 32 cognition training tasks for attention/concentration, reaction behavior, memory , logical reasoning \& executive functioning with graded difficulty . It is composed of regular PC , 1G RAM , DVD drive, 100 GB hard drive with windows XP SP3, 128 MB RAM direct 3D graphic card , Screen at least 19 , regular PC keyboard or Rehacom panel \& printer .The Rehacom software version is (patientenpult (1990-1997) EN/ISO-13485-certified).~* For each Cognitive training domain there is one hundred levels of difficulty.~* Each patient is evaluated from level one(1) ang gradually increase the difficulty till we reach the level that will be used in the treatment sessions as the patient's performance improve we can proceed to the next level.~* The period of the session was chosen to be maximum (60 minutes) for each patient with five minutes rest in between each level.
Study NCT06104072 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Designed Physical Therapy Program
Description: a designed physiotherapy program consisted of aerobic exercise on treadmill, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Graduated active exercises, gait training, Reciprocal and weight shifting exercises.
Study NCT06104072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Designed Physical Therapy Program
Description: a designed physiotherapy program consisted of aerobic exercise on treadmill, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Graduated active exercises, gait training, Reciprocal and weight shifting exercises.
Study NCT05155137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Capsule (Valsartan + Amlodipine + Rosuvastatin)
Description: Polypill with 3 medications (Valsartan 80 mg + Amlodipine 5 mg + Rosuvastatin 10 mg)
Study NCT05155137 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stroke Riskometer
Description: Participants will be randomized to use Stroke Riskometer App for lifestyle modifications
Study NCT05155137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Riskometer
Description: Participants will be randomized to use Stroke Riskometer App for lifestyle modifications
Study NCT05350371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone Oral Tablet
Description: Patients in the pirfenidone treatment arm will be given pirfenidone 267mg tablet, tid for 1 day followed by dose escalation to two 267 mg tablet tid for 6 days. Thus, the treatment will be for total of 7 days or till patients develop an adverse event that requires their participation in the study to be stopped.
Study NCT05350371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo tablets will be an exact replica of the pirfenidone tablet.
Study NCT06789926 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention Group
Description: Attending a 4-hour ACT workshop, and after attending participants will utilize the remaining course time to independently access the LINE platform. The platform will feature pre-recorded guided audio files for relaxation, emotional videos, and psychological cards.
Study NCT05135325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient portal message
Description: Portal message encourages patients to donate blood
Study NCT05135325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social responsibility
Description: Message specifies that there is a shortage of the patient's blood type
Study NCT06060886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Oral dose range 5-30 mg/day (100 mg- 600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence.
Study NCT06060886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Oral dose range 3-12 mg/day (150mg-600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence
Study NCT06282874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib 100 mg once daily on days 1 to 28 of each 28-day cycle
Study NCT04792268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to eCDSS on wards
Description: Electronic clinical decision support (eCDSS) will be available to clinicians on wards recruited to this arm.~An eCDSS is a health information technology system designed to assist clinicians and other health care professionals in clinical decision-making.~The key digital tool to be used for eCDSS in this study is CogStack. This eCDSS has been developed to alert clinicians automatically regarding patients admitted under their care, triggered by the presence of new, old or absent HbA1c pathology reports on the electronic health record (EHR).
Study NCT05047380 — intervention group
Intervention type: BEHAVIORAL
Intervention: Owstery Disability Scale for disability Beck Depression Scale, Beck Anxiety Scale for psychological evaluation, VAS for pain, Pittsburgh Sleep Quality Scale for sleep quality
Description: All assessments will be made using questionairres. The Oswestry Disability Index scale will be filled in to assess the severity of disability resulting from pain in the patient. Pain severity will be evaluated with the Visual Analog Scale (VAS). Depression and anxiety assessment will be made with Beck Depression Scale and Beck Anxiety Scale, respectively. Sleep quality will be evaluated with the Pittsburg Sleep Quality Index.
Study NCT06097572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intranasal food challenge
Description: Subjects will undergo an incremental intranasal challenge to initially 0.9% NaCl saline solution, and then increasing doses of the food protein
Study NCT06097572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mast cell activation test
Description: Blood will be processed for mast cell activation as previously described (https://doi.org/10.1016/j.jaci.2018.01.043)
Study NCT06783348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Administeration by intravenous infusion or injection at an activity of 7.4 GBq every 6 weeks (±1 week) for up to a total of 6 doses, unless there is disease progression or unacceptable toxicity or until the occurrence of a withdrawal criterion. The first infusion should be administered within 3 weeks from enrolment. Patients in PR or SD after 4 cycles will receive an additional two doses.
Study NCT05989347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: 10 mg tablets for oral administration daily throughout chemotherapy treatment
Study NCT06142552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRSW117
Description: once a week, 50 weeks and as needed
Study NCT05206539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Self-assembling peptide (P11-4)
Description: Prior to application, teeth are isolated by cotton rolls and gently air dried. The surface of the lesion is conditioned with a 2% sodium hypochlorite solution for 20 s and then rinse with water. Application of 35% phosphoric acid etching gel for 20 sec followed by rinsing with water-air spray for 30 sec. Drying the surface with compressed oil-free air for 60 sec. Curodont Repair is dissolve in 0.05 ml of distilled water and applied to the surface and allowed to work for about 5 min.~Participants will receive oral hygiene instructions.
Study NCT05206539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPP-ACFP
Description: Prior to application, teeth are isolated by cotton rolls and gently air dried. Application of fluoride varnish with a brush applicator on the surface of the teeth for 5 minutes. Patients is advising not to brush their teeth or chew food for at least 4 h after treatment.~Participants will receive oral hygiene instructions
Study NCT05206539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resin infiltration
Description: The validated ICON Vestibular (DMG) infiltration lesion infiltration protocol is applied. Icon Etch (DMG) etching gel containing 15% hydrochloric acid is applied for 120 seconds using an applicator. It is then removed by rinsing thoroughly with water-air spray for 30 seconds. Then follows application of pure alcohol - Icon Dry (DMG) for 30 seconds for complete drying of the lesion and additional drying compressed oil-free air for 40 sec. Application of Icon Infiltrant (DMG) using a microapplicator allows it to penetrate for 3 minutes, during which, if necessary, it is reapplied several times. Excess material is removed with dry microbrushes and followed by light curing for 40 seconds. Re-applying of the infiltrate for 1 minute, removal of excess material, light curing for 40 seconds. Participants will receive oral hygiene instructions
Study NCT05206539 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group, No Treatment
Description: Everyday oral hygiene instructions Subjects will receive non-prescription fluoride toothpaste (1400 ppm Fluoride, Elmex junior) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate and rinse.
Study NCT05389696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single subcutaneous administration and Blood collection
Description: Single subcutaneous administration and Blood collection
Study NCT05389696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single subcutaneous administration and then IV injection.
Description: Single subcutaneous administration and then single intravenous administration after 2 weeks. In addition Blood collection is conducted as scheduled.
Study NCT05389696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIT-001 20mg and 40mg_Multiple administration
Description: Multiple subcutaneous administration for 7 days and then blood collection
Study NCT05057208 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID
Description: COVID vaccination
Study NCT05008770 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06789835 — intervention group
Intervention type: DEVICE
Intervention: Fluorescence imaging of disclosed and undisclosed plaque
Description: Teeth are imaged using a fluorescence camera/an intraoral scanner before and after plaque disclosure.
Study NCT06788483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An self-regulated flipped classroom strategy
Description: The self-regulated flipped classroom strategy was developed based on the self-regulated learning theory (Zimmerman, 2002) and the flipped classroom model (Bishop \& Verleger, 2013).
Study NCT06790212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab
Description: 20mg/kg Q3W，D1
Study NCT06790212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin，130mg/m2，D1，Q3W；
Study NCT06790212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin，130mg/m2，D1，Q3W；